North Perth biomedical company BioPharmica Ltd subsidiary Molecular Discovery Systems has entered into a collaborative research agreement with General Electric Healthcare, in a partnership Premier Alan Carpenter has labelled a win for WA's biotech industry.
The companies have recognised the MDS labs at the Western Australian for Medical Research, home of the WA Research Tissue Network, as a specialty imaging site and key location to showcase current and future GE Healthcare imaging technologies to partners and customers in the Asian region.
The companies will also conduct a pilot study into the links between a patient's genes and incidences of breast cancer through the use of GE provided technology.
MDS researchers will also work with GE Healthcare teams in the US, UK, Australia and Singapore, focusing on the application and extension of cell-based imaging technology in cancer patient tissue samples and imaging assays. Further to this, MDS will provide additional consultancy services to GE Healthcare and its customers.
BioPharmica director Charles Murphy said the GE collaboration would support mutual goals.
"In some areas of the collaboration one party will own intellectual property and in other areas MDS and GE Healthcare will share it," he said.
"Both MDS and GE Healthcare are seeking to invrease the impact of cell-based imaging on research and patient care."
